Information related to the presentations is as follows: -0-
Presentation Title: "The dual ABL/SRC inhibitors dasatinib, SKI-606, and INNO-406 are potent inhibitors of T cell acute lymphoblastic leukemia cell lines expressing the NUP214-ABL1 fusion kinase" Abstract Number: 1825 Session: Poster Section 7, Clinical Research 8, Poster Board #11 Session Date and Time: Monday, April 16, 2007, 8:00 a.m. - 12:00 p.m. Location: Exhibit Hall, Los Angeles Convention Center Presentation Title: "Cell death and autophagy induced by INNO-406, a novel Bcr-Abl inhibitor, in Philadelphia leukemias" Abstract Number: 2768 Session: Poster Section 10, Cellular and Molecular Biology 31, Poster Board #17 Session Date and Time: Monday, April 16, 2007, 1:00 p.m. - 5:00 p.m. Location: Exhibit Hall, Los Angeles Convention Center-0-
Presentation Title: "Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib, and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with bcr-abl gene amplification" Abstract Number: 3246 Session: Poster Section 29, Experimental and Molecular Therapeutics 26, Poster Board #8 Session Date and Time: Monday, April 16, 2007, 1:00 p.m. - 5:00 p.m. Location: Exhibit Hall, Los Angeles Convention Center
INNO-406 (formerly known as NS-187) is an orally bioavailable, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor currently in Phase I clinical studies. According to a study published in the journal Blood (Dec. 1, 2005), INNO-406 is 25 to 55 times more potent than imatinib in vitro, and at least 10 times as effective as imatinib mesylate in suppressing the growth of Bcr-Abl bearing tumors. INNO-406 has demonstrated activity in 12 of 13 imatinib-resistant cell lines. In addition to its Bcr-Abl inhibitory properties, INNO-406 inhibits Lyn kinase. Upregulation of Lyn kinase activity is a well recognized cause of imatinib resistance. Lyn kinase activation has also been documented in a variety of solid tumors, including prostate cancer.
About INNOVIVE Pharmaceuticals
INNOVIVE Pharmaceuticals, Inc. acquires, develops and commercializes novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. The company has four drug programs in clinical development: INNO-406, Tamibarotene, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, acute promyelocytic leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively. For additional information visit www.innovivepharma.com.
President and CEO
Porter Novelli Life Sciences
Media & Investor Relations